LLYLoxo Oncology, Inc.Running, no new patients
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Lymphoma, Mantle-Cell
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 500 (planned)
- Started
- Apr 8, 2021
- Main results expected
- Nov 2027
- Fully finished
- Jun 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)
Measured over: Up to approximately 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04662255 · record last updated 2026-09-23 · checked 2026-11-09 15:36 UTC